Related Experiment Video
Updated: Jan 18, 2026
Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery
Published on: October 4, 2018
Flow Cytometric Immunophenotypic Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms
1Flow Cytometry and Hematopathology Section, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, Maryland, 20892.
Insights
Flow cytometry is crucial for diagnosing plasma cell neoplasms and monitoring minimal residual disease after treatment. Integrating these findings with other clinical data is essential for accurate patient management.
Area of Science:
- Clinical cytometry
- Hematology
- Oncology
Background:
- Plasma cell neoplasms require accurate diagnosis and monitoring.
- Flow cytometric immunophenotyping offers valuable insights.
- Assessing minimal residual disease is critical for treatment efficacy.
Purpose of the Study:
- To review the applications of flow cytometry in plasma cell neoplasms.
- To highlight its role in differential diagnosis and minimal residual disease monitoring.
- To emphasize the integration of flow cytometry with other diagnostic modalities.
Main Methods:
- Review of current literature on flow cytometric immunophenotyping.
- Analysis of diagnostic and prognostic applications in plasma cell neoplasms.
- Discussion of challenges and strategies in targeted therapy settings.
Main Results:
- Flow cytometry aids in differentiating plasma cell neoplasms.
- It is effective for monitoring minimal residual disease post-therapy.
- Integration with clinical and other data improves diagnostic accuracy.
Conclusions:
- Flow cytometric immunophenotyping is indispensable for plasma cell neoplasms.
- Comprehensive data integration is key for optimal patient care.
- Strategies for evaluating plasma cells under targeted therapy are evolving.
Abstract:
This review focuses on the roles of flow cytometric immunophenotyping has in the differential diagnosis of plasma cell neoplasms and the post-therapy monitoring of minimal (measurable) residual disease. The need to integrate flow cytometry data with clinical, laboratory, radiographic, morphological, and molecular genetic findings is emphasized. The challenges of and strategies for evaluating plasma cells in the setting of targeted therapy are also highlighted. © 2019 International Clinical Cytometry Society.
